期刊文献+

分子成像与肿瘤靶向治疗 被引量:2

Molecular imaging and tumor targeted therapy
下载PDF
导出
摘要 肿瘤关键分子靶点的异常表达(表达水平和表达状态)与分子靶向治疗反应、治疗效果及预后密切相关。因此,精准评价肿瘤关键分子表达水平和表达状态,无论在肿瘤分子靶向治疗开展前、过程中以及治疗后均显得尤为关键。分子成像可以无创、实时而全面地对肿瘤关键靶点的表达水平及表达状态进行定性、定量研究,对筛选优势人群、指导治疗、判断预后具有重大意义。本文简述基于不同分子探针的分子成像技术在肿瘤靶向治疗过程中的应用,对比分析分子成像在靶向治疗中的价值,以期有益于新型治疗策略的开发。 The abnormal expression (level and status) of the key molecular targets of tumors is related to molecular targeted therapy response, effect, and prognosis. Therefore, the expression level and status of key molecular targets of tumors must be accurately evalu-ated, regardless of the status before, during, and after receiving targeted therapy. Molecular imaging is a non-invasive method used for qualitative and quantitative research on key molecular targets of tumor in vivo and in real-time. This technique is also employed to screen treatment beneficiaries, guide therapy, and evaluate prognosis. This paper reviews the application progress of molecular imag-ing using various probes in cancer targeted therapy. The clinical value of molecular imaging in tumor targeted therapy is further ana-lyzed to promote the development of novel targeted therapy for tumors.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2016年第11期475-479,共5页 Chinese Journal of Clinical Oncology
基金 国家重点基础研究发展计划(编号:2015CB931800) 国家自然科学基金项目(编号:81471724 81101088 81130028 31210103913) 黑龙江省自然科学基金委留学归国科学基金(编号:LC2013C26) 黑龙江省级领军人才梯队后备带头人资助资金 哈尔滨市科技创新人才研究专项资金(编号:2014RFQGJ011) 哈尔滨医科大学伍连德青年科学基金(编号:WLD-QN1119) 哈尔滨医科大学附属第四医院杰出青年基金 黑龙江省高校分子影像重点实验室基金资助~~
关键词 分子成像 临床应用 肿瘤分子靶向治疗 molecular imaging clinical application tumor molecular targeted therapy
  • 相关文献

参考文献34

  • 1Herbst RS,Heymach JV,Lippman SM.Lung cancer[J].N Engl J Med,2008,359 (13) : 1367 -1380.
  • 2Cancer Genome Atlas Research Network.Comprehensive genomic characterization of squamous cell lung cancers[J].Nature,2012,489 (7417) : 519 -525.
  • 3Keller KE,Tan IS,Lee YS.SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions[J].Science,2012,338 (6110) : 1069 -1072.
  • 4Henry NL,Hayes DF.Cancer biomarkers[J].Mol Oncol,2012,6 (2) : 140 -146.
  • 5Shankar LK.The clinical evaluation of novel imaging methods for cancer management[J].Nat Rev Clin Oncol,2012,9 (12) : 738 -744.
  • 6Kocher B,Piwnica-Worms D.Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo[J].Cancer Discov,2013,3 (6) : 616 -629.
  • 7Van Dam GM,Themelis G,Crane LM,et al.Intraoperative tumorspecific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results[J].Nat Med,2011,17 (10) : 1315 -1319.
  • 8Burggraaf J,Kamerling IM,Gordon PB,et al.Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met[J].Nat Med,2015,21 (8) : 955 -961.
  • 9Muzi M,O'sullivan F,mankoff DA,et al.quantitative assessment of dynamic PET imaging data in cancer imaging[J].Magn Reson Imaging,2012,30 (9) : 1203 -1215.
  • 10Mountz JM,Yankeelov TE,Rubin DL,et al.Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials[J].J Clin Oncol,2014,32 (19) : 2115 -2116.

同被引文献29

  • 1ZHENG R,ZENG H,ZHANG S,et al.National estimates of cancer prevalence in China,2011[J].Cancer Lett,2016,370(1):33-38.
  • 2PAUL A,JEFFREY B.Stereotactic body radiation therapy for stage I non-small cell lung cancer[J].Thorac Surg Clin,2016,26(3):261-169.
  • 3SHINYA H,HIDEKAZU T,HIROAKI H.Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non -small cell lung cancer : Evaluation of mass -like fibrosis [J].Thoracic Cancer,2015,6(2):186-193.
  • 4JfiRfiMIE C,SfiBASTIEN T,BERNARD D,et al.Areas of high 18F -FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer[J].J Nuclear Med,2015,26(2);196-203.
  • 5MASAHIKO A,HIROYOSHI A,MARIKO S,et al.Impact of pretreatment whole -tumor perfusion computed tomography and 18F -fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy [J].J Radia Res,2016,57(s1):1-8.
  • 6HIDEKAZU T,SHINYA H,HIROAKI H.Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy [J].Asia-Pacific Journal of Clinical Oncol,2016,12(1): e113-e117.
  • 7NA FF,WANG JW,LI C,et al.Primary tumor standardized uptake value measured on F18- Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non -small -cell lung cancer receiving radiotherapy : meta-analysis[J].Thorac Oncol.2014,9(6):834-42.
  • 8YOKO S,ATSUSHI N,HIROSHI 0,et al.Value of dual time point F -18 FDG -PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non -small cell lung cancer treated with stereotactic body radiation therapy [J].European Journal of Radiology,2012,81(11):3530-3534.
  • 9PIERRE L,ZSOLT U,PHILIPPE C,et al.FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy [J].Eur J Nucl Med Mol Imaging,2016,43(8):1453-1460.
  • 10YOKO S,HIROSHI O,ATSUSHI N,et al.Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy : prognostic value[J].Radiology,2014,270(1):275-281.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部